Pfizer (PFE) Tops Q3 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
PFIZER REPORTS THIRD-QUARTER 2015 RESULTS
October 27, 2015 6:45 AM EDTThird-Quarter 2015 Reported Revenues(1) of $12.1 Billion Increased 6% Operationally, Which Includes $0.3 Billion Reflecting One Month of Legacy Hospira U.S. Operations Third-Quarter 2015 Adjusted Diluted EPS(2) of $0.60 and Reported Diluted EPS(1) of $0.34, Which Includes One Month of Legacy Hospira U.S. Operations Third-Quarter 2015 Reported Revenues(1) for Pfizer-Standalone (Excluding Legacy Hospira) Increased 4% Operationally; Innovative Products Business Grew 21% Operationally, Primarily Driven by Prevnar 13 Adult and Ibrance Raised Midpoint of 2015 Financial Guidance Ranges for Reported Revenues(1) by $1.0 Billion and Adjusted Diluted EPS(2) by $0.11, Primarily Reflecting Strong Performance to Date and Improved... More
